Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

KOL Strategy

- PMLiVE

Long-term study reveals ‘ever-changing’ nature of lung cancer

The researchers hope the findings could help doctors to tailor treatments for individual patients

- PMLiVE

Study unveils ‘breakthrough biomarker’ for Parkinson’s disease

Researchers say they can measure a protein to determine the likelihood that someone will develop the disease

- PMLiVE

The PM Society Digital Awards 2023

The PM Society Digital Awards 2023 are open for entries!

Avocado and toast

What are the ingredients for a perfect partnership?

Perfect partnerships can take many forms. Just like avocado and toast or tea and biscuits, all good on their own, but better together.

Cuttsy + Cuttsy

Mednet Mental Health Strategy 2023

We've launched our mental health strategy for the year to support our colleagues in maintaining positive mental health.

Mednet

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

Merck KGaA’s MS drug put on partial clinical hold by FDA

Laboratory results suggested there were two cases of drug-induced liver injury during the phase 3 studies

Charitable programme: Cuttsy Cares

Cuttsy Cares Continues…

Cuttsy+Cuttsy's charitable programme — Cuttsy Cares — has been running for the past 2 years, providing the team with the opportunity to support causes close to their hearts.

Cuttsy + Cuttsy

B-lown away by our first CDP rating

A catch up with Louise Jones, Cuttsy+Cuttsy's sustainability officer, on what was achieved in 2022, the agency's latest environmental assessment with CDP and a look ahead to 2023.

Cuttsy + Cuttsy

- PMLiVE

The importance of creativity in content

By Louise Barry

- PMLiVE

Novo Nordisk and Aspect Biosystems partner in billion dollar deal for diabetes treatments

The deal to develop a new class of disease-modifying treatments could be worth up to $2.6bn

- PMLiVE

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Biotheryx will receive up to $347m in potential milestone payments

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links